Last reviewed · How we verify

Paroxetine CR and Paroxetine IR

GlaxoSmithKline · Phase 1 active Small molecule

Paroxetine CR and Paroxetine IR is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development.

At a glance

Generic nameParoxetine CR and Paroxetine IR
SponsorGlaxoSmithKline
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Paroxetine CR and Paroxetine IR

What is Paroxetine CR and Paroxetine IR?

Paroxetine CR and Paroxetine IR is a Small molecule drug developed by GlaxoSmithKline.

Who makes Paroxetine CR and Paroxetine IR?

Paroxetine CR and Paroxetine IR is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is Paroxetine CR and Paroxetine IR in?

Paroxetine CR and Paroxetine IR is in Phase 1.

Related